INVIVYD INC. - COMMON

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

26 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

22 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd to Participate at the Jefferies Healthcare Conference

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

11 May 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

04 May 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference

25 Apr 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

25 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

12 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19

30 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

23 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

22 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights

16 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Changes to Executive Team

03 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

06 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

17 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

10 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference

09 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

02 Nov 2022 07:00:02 By Nasdaq GlobeNewswire